Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2026
Long-Term Outcome of Integrative Care for Biliary Atresia: 17 Years of Experience in a Single Center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kadohisa Masashi, Inomata Yukihiro, Shimata Keita, Kawabata Seiichi, Yoshii Daiki, Isono Kaori, Honda Masaki, Hayashida Shintaro, Ohya Yuki, Hibi Taizo
Аннотация
OBJECTIVES: Integration of the treatment for biliary atresia, including Kasai portoenterostomy and liver transplant, has had an important role in the marked improvement of the prognosis. We reviewed our experience with Kasai portoenterostomy and living donor liver transplant, both performed by the same pediatric surgical team and described the clinical features and outcomes of patients with biliary atresia.
MATERIALS AND METHODS: We reviewed 41 patients with biliary atresia who underwent Kasai portoenterostomy at Kumamoto University from August 2000 to March 2017.
RESULTS: The median age at Kasai portoenterostomy was 63 days (IQR, 54-75 days). Jaundice clearance was achieved by 23 patients (56.1%) at any time during the postoperative course. The 1-year, 5-year, 10-year, and 20-year native liver survival rates were 51.2%, 46.3%, 43.0%, and 38.3%, respectively. Of 41 patients, 24 eventually underwent living donor liver transplant. Of these, 22 patients underwent transplant during infancy or early childhood; their median age and body weight at living donor liver transplant were 6.5 months (IQR, 5.3-8.0 months) and 7.0 kg (IQR, 6.4-8.0 kg), respectively. The most common indication for living donor liver transplant was jaundice-induced liver cirrhosis; other indications included portal hyper-tension and recurrent cholangitis. The 15-year overall survival rate of 22 patients was 90.9%.
CONCLUSIONS: Patients with biliary atresia treated by our team capable of both Kasai portoenterostomy and living donor liver transplant have shown good long-term outcomes. However, further improvement of Kasai portoenterostomy and timely living donor liver transplant remain crucial.
MATERIALS AND METHODS: We reviewed 41 patients with biliary atresia who underwent Kasai portoenterostomy at Kumamoto University from August 2000 to March 2017.
RESULTS: The median age at Kasai portoenterostomy was 63 days (IQR, 54-75 days). Jaundice clearance was achieved by 23 patients (56.1%) at any time during the postoperative course. The 1-year, 5-year, 10-year, and 20-year native liver survival rates were 51.2%, 46.3%, 43.0%, and 38.3%, respectively. Of 41 patients, 24 eventually underwent living donor liver transplant. Of these, 22 patients underwent transplant during infancy or early childhood; their median age and body weight at living donor liver transplant were 6.5 months (IQR, 5.3-8.0 months) and 7.0 kg (IQR, 6.4-8.0 kg), respectively. The most common indication for living donor liver transplant was jaundice-induced liver cirrhosis; other indications included portal hyper-tension and recurrent cholangitis. The 15-year overall survival rate of 22 patients was 90.9%.
CONCLUSIONS: Patients with biliary atresia treated by our team capable of both Kasai portoenterostomy and living donor liver transplant have shown good long-term outcomes. However, further improvement of Kasai portoenterostomy and timely living donor liver transplant remain crucial.